Up to 10% of cancers are attributable to inherited gene mutations, such as
BRCA1/2 and those associated with Lynch syndrome.
1 Identifying mutation carriers is critical for treatment decisions, cancer prevention, and early detection.
2 Despite the importance of equal access to testing, there is some evidence for disparities by education level, insurance status, and race/ethnicity.
3 Although carrier rates are equivalent between men and women, there may also be a gender disparity in testing.
4 To date, however, epidemiological studies have largely focused on genetic testing in women and hereditary breast and ovarian cancer (HBOC).
5 This study describes the US national distribution of genetic testing for hereditary cancer risk, identifies disparities, and assesses whether a gender gap in testing exists.